CERETEC
Details
- Status
- Prescription
- First Approved
- 1988-12-30
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CERETEC Approval History
What CERETEC Treats
3 indicationsCERETEC is approved for 3 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Stroke
- Intra-Abdominal Infection
- Inflammatory Bowel Disease
Drugs Similar to CERETEC
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CERETEC FDA Label Details
ProIndications & Usage
FDA Label (PDF)Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.